

Drug resistance interpretation: PR

HIVDB 9.5.1 (2023-11-05)

PI Major Mutations:None

PI Accessory Mutations:None

PR Other Mutations:I13V ^{10%}_{pos:2,571} • G16E ^{100%}_{pos:2,835} • R41K ^{10%}_{pos:1,842} • L63Q ^{10%}_{pos:2,858} • I64V ^{10%}_{pos:2,858} • E65D ^{100%}_{pos:2,311} • I72IV ^{0-100%, 1-10%}_{pos:3,323} • V77I ^{10%}_{pos:2,111}

Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
fosamprenavir/r (FPV/r)	Susceptible
indinavir/r (IDV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible
nelfinavir (NFV)	Susceptible
saquinavir/r (SQV/r)	Susceptible
tipranavir/r (TPV/r)	Susceptible

Mutation scoring: PR

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations:None

NNRTI Mutations:None

RT Other Mutations:V35T ^{100%}_{pos:1,271} • E40D ^{10%}_{pos:1,222} • K49R ^{100%}_{pos:1,217} • K122E ^{100%}_{pos:1,227} • D123S ^{10%}_{pos:1,982} • I135T ^{100%}_{pos:1,585} • S162A ^{100%}_{pos:444} • T165I ^{100%}_{pos:522} • E169D ^{100%}_{pos:1,522} • K173A ^{10%}_{pos:535} • Q174K ^{10%}_{pos:535} • V179V ^{1-100%, 0-100%}_{pos:727} • G196GE ^{0-100%, 0-10%}_{pos:1,591} • T200A ^{100%}_{pos:1,112} • Q207A ^{10%}_{pos:1,142} • R211S ^{10%}_{pos:1,091} • V243KQ ^{0-100%, 0-10%}_{pos:479} • D250E ^{10%}_{pos:1,079} • A354N ^{100%}_{pos:145} • K356KR ^{0-100%, 0-10%}_{pos:1,013}

Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible	doravirine (DOR)	Susceptible
zidovudine (AZT)	Susceptible	efavirenz (EFV)	Susceptible
stavudine (D4T)	Susceptible	etravirine (ETR)	Susceptible
didanosine (DDI)	Susceptible	nevirapine (NVP)	Susceptible
emtricitabine (FTC)	Susceptible	rilpivirine (RPV)	Susceptible
lamivudine (3TC)	Susceptible		
tenofovir (TDF)	Susceptible		

RT comments

Other

- V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for NRTI.

No drug resistance mutations were found for NNRTI.

Drug resistance interpretation: IN

HIVDB 9.5.1 (2023-11-05)

INSTI Major Mutations:None

INSTI Accessory Mutations:None

IN Other Mutations:S17N ^{10%}_{pos:625} • L45V ^{10%}_{pos:714} • M50L ^{10%}_{pos:765} • I72V ^{10%}_{pos:123} • T112IV ^{1-100%, 0-10%}_{pos:481} • I113V ^{10%}_{pos:481} • T124N ^{100%}_{pos:528} • T125A ^{10%}_{pos:528} • V201I ^{100%}_{pos:521} • A205AS ^{0-100%, 0-10%}_{pos:513} • T206S ^{10%}_{pos:527} • K211Q ^{10%}_{pos:514} • L234I ^{100%}_{pos:520} • D286N ^{100%}_{pos:1,947}

Integrase Strand Transfer Inhibitors	
bictegravir (BIC)	Susceptible
cabotegravir (CAB)	Susceptible
dolutegravir (DTG)	Susceptible
elvitegravir (EVG)	Susceptible
raltegravir (RAL)	Susceptible

Mutation scoring: IN

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for INSTI.